




Healthcare Industry News: Carbon Fiber
News Release - October 15, 2018
CIVCO Radiotherapy Announces FDA 510k Clearance and CE Mark of their Solstice SRS Immobilization System
CORALVILLE, Iowa, Oct. 15, 2018 -- (Healthcare Sales & Marketing Network) -- CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, is delighted to announce FDA 510k clearance and EU CE mark for their Solstice™ SRS Immobilization System. The product will be available for shipment following its display at the American Society for Radiation Oncology (ASTRO) Meeting taking place October 21-24, 2018 in San Antonio, Texas."The Solstice SRS Immobilization System is the only midline thermoplastic mask system on the market with variable pitch capability, increasing setup options in CT simulation and allowing positioning flexibility during treatment," commented John Steffen, Director of Product Management at CIVCO. "We are excited that clearance in the U.S. and EU CE marking opens opportunities for us to provide this unique solution to radiotherapy clinics to help improve patient outcomes."
For more information or to schedule a demo, visit www.CivcoRT.com or Booth #2833 during ASTRO.
About CIVCO Radiotherapy
CIVCO Radiotherapy has over 35 years' experience developing, manufacturing and providing high-quality, innovative, patient-centric solutions in radiotherapy. These solutions include: advanced patient immobilization and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products and advanced 6DOF robotic patient positioning. Corporate information is available at www.CivcoRT.com.
COPYRIGHT © 2018. CIVCO IS A REGISTERED TRADEMARK OF CIVCO MEDICAL SOLUTIONS. SOLSTICE IS A TRADEMARK OF CIVCO. ALL PRODUCTS MAY NOT BE LICENSED IN ACCORDANCE WITH CANADIAN LAW.
Source: CIVCO Radiotherapy
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.